Skip to Content

Aristada Approval History

  • FDA approved: Yes (First approved October 5th, 2015)
  • Brand name: Aristada
  • Generic name: aripiprazole lauroxil
  • Dosage form: Injection
  • Company: Alkermes, Inc.
  • Treatment for: Schizophrenia

Aristada (aripiprazole lauroxil) is an extended-release injectable atypical antipsychotic with one-month, six-week, and two-month dosing options for the treatment of schizophrenia.

Development History and FDA Approval Process for Aristada

Jun  6, 2017Approval FDA Approves Two-Month Aristada for Treatment of Schizophrenia
Oct  6, 2015Approval FDA Approves Aristada (aripiprazole lauroxil) for Schizophrenia
Aug 21, 2015Alkermes Provides Update on FDA Review of Aristada for the Treatment of Schizophrenia
Jun  9, 2015Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published in Journal of Clinical Psychiatry

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.